NetDragon Leads Government-Backed AI Push to Build Thailand's Future Workforce
prnewswire.com
Want to monitor XBIT?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor XBITxbiotech is developing a first-in-class monoclonal antibody (mabp1) to inhibit chronic inflammation. chronic (sterile) inflammatory responses are involved in the progression of many serious and common diseases. mabp1 is being investigated in many important areas of medicine, including: cancer, leukemia (phase 1); type 2 diabetes (phase2); psoriasis (phase 2); and vascular disease (phase 2).